The FDA approval of Novartis' Cosentyx as the first intravenous interleukin-17A antagonist for rheumatic diseases could potentially increase the company's market share in the rheumatic diseases treatment market. This is because the approval could lead to increased sales of Cosentyx, which would in turn increase Novartis' revenues. Furthermore, the approval could also enhance Novartis' reputation as a leader in the development of innovative treatments for rheumatic diseases.